The first generic version of Accutane (isotretinoin), approved Nov. 11 by the FDA, reached market in late November at a price approximately 5.5 percent lower than the brand name.
Lebrikizumab Demonstrates Promising Results in Atopic Dermatitis
The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques
Highlights from AAD 2023
The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice
New Technology Could Allow Us to Rethink Alopecia Scores
Upadacitinib Advances to Phase 3 Clinical Trials in Systemic Lupus Erythematosus